Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probio-Tec AB-25
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probio-Tec AB-25 is a probiotic dietary supplement formulated as a mixture of two specific bacterial strains: Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12. It is designed to support digestive health and immune function by modulating the gut microbiota. The product has been clinically tested, including in randomized controlled trials for maintenance of remission in ulcerative colitis, though no significant clinical benefit was demonstrated compared to placebo in that indication[5][3][9]. The formulation typically includes these live bacteria delivered in an oil base (such as sunflower oil), and it is suitable for use across various age groups, including infants[4]. Developed with expertise from Chr. Hansen, a leading probiotics developer, the strains used are well-characterized and widely studied.
- Brand names
- Probio-Tec AB-25
- Other names
- Lactobacillus acidophilus La-5 + Bifidobacterium animalis subsp. lactis BB-12Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis (BB12)
Beyond the preview
Go deeper on Probio-Tec AB-25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probio-Tec AB-25.